{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-26-000021","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2026-07-06T20:12:09+00:00","discovered_at":"2026-07-06T20:13:03.311378+00:00","generated_at":"2026-07-06T20:13:07.504332+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AbbVie lowers Q2 and FY 2026 adjusted EPS guidance by $0.17 on $291M IPR&D expense","bullets":["Q2 2026 adjusted diluted EPS guidance reduced to $3.57-$3.61 from $3.74-$3.78.","Full-year 2026 adjusted diluted EPS guidance reduced to $13.91-$14.11 from $14.08-$14.28.","$291M pre-tax acquired IPR&D and milestones expense incurred in Q2 2026.","Expense relates to collaborations, licensing, and asset acquisitions; not previously forecasted."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-26-000021","json":"https://secwatch.observer/filing/0001551152-26-000021.json","markdown":"https://secwatch.observer/filing/0001551152-26-000021.md","text":"https://secwatch.observer/filing/0001551152-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/0001551152-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260706.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T20:13:07.504332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}